CoChat

The anti-estrogen receptor drug, tamoxifen, is selectively Lethal to P-glycoprotein-expressing Multidrug resistant tumor cells

Open access
Bakadlag, Rowa, Limniatis, Georgia, Georges, Gabriel, Georges, Elias · 2023 · BMC Cancer

Published version of a preprint

The DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.

Abstract

Background: P-glycoprotein (P-gp), a member of the ATP Binding Cassette B1 subfamily (ABCB1), confers resistance to clinically relevant anticancer drugs and targeted chemotherapeutics. However, paradoxically P-glycoprotein overexpressing drug resistant cells are “collaterally sensitive” to non-toxic drugs that stimulate its ATPase activity. Methods: Cell viability assays were used to determine the effect of low concentrations of tamoxifen on the proliferation of multidrug resistant cells (CHO R C5 and MDA-Doxo 400 ), expressing P-gp, their parental cell lines (AuxB1 and MDA-MB-231) or P-gp-CRISPR knockout clones of AuxB1 and CHO R C5 cells. Western blot analysis was used to estimate P-gp expression in different cell lines. Apoptosis of tamoxifen-induced cell death was estimated by flow cytometry using Annexin-V-FITC stained cells. Oxidative stress of tamoxifen treated cells was determined by measuring levels of reactive oxygen species and reduced thiols using cell-permeant 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) and 5,5-dithio-bis-(2-nitrobenzoic acid) DTNB, respectively. Results: In this report, we show that P-gp-expressing drug resistant cells (CHO R C5 and MDA-Doxo 400 ) are collaterally sensitive to the anti-estrogen tamoxifen or its metabolite (4-hydroxy-tamoxifen). Moreover, P-gp-knockout clones of CHO R C5 cells display complete reversal of collateral sensitivity to tamoxifen. Drug resistant cells exposed to low concentrations of tamoxifen show significant rise in reactive oxygen species, drop of reduced cellular thiols and increased apoptosis. Consistent with the latter, CHO R C5 cells expressing high levels of human Bcl-2 (CHO R C5-Bcl-2) show significant resistance to tamoxifen. In addition, the presence of the antioxidant N-acetylcysteine or P-gp ATPase inhibitor, PSC-833, reverse the collateral sensitivity of resistant cells to tamoxifen. By contrast, the presence of rotenone (specific inhibitor of mitochondria complex I) synergizes with tamoxifen. Conclusion: This study demonstrates the use of tamoxifen as collateral sensitivity drug that can preferentially target multidrug resistant cells expressing P-gp at clinically achievable concentrations. Given the widespread use of tamoxifen in the treatment of estrogen receptor-positive breast cancers, this property of tamoxifen may have clinical applications in treatment of P-gp-positive drug resistant breast tumors. Graphical Abstract:

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12885-022-10474-x

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Collateral sensitivity of drug resistant cells to tamoxifen is dependent on P-gp expression- Panel (A) shows a Western blot analysis demonstrating the expression of P-gp in total protein extracts from wild-type Chinese hamster ovary cells (AuxB1), drug resistant selected cells (CHORC5), P-gp-knockout drug sensitive cells (AuxB1ΔP−gp), and P-gp-knockout CHORC5 (CHORC5ΔP−gp−A1, and CHORC5ΔP−gp−A3) cells, probed with P-gp-directed monoclonal antibody (C219 mAb) and anti-α-tubulin. α-tubulin expression is shown as a loading control. Panel (B) shows the proliferation of the above cell lines (AuxB1, CHORC5, AuxB1ΔP−gp, CHORC5ΔP−gp−A1, and CHORC5ΔP−gp−A3) without or with increasing molar concentrations of colchicine (0–10 µM) or tamoxifen (0–50 µM). Graphs represent the mean ± SD of three independent experiments done in triplicate
Fig. 1 Collateral sensitivity of drug resistant cells to tamoxifen is dependent on P-gp expression- Panel (A) shows a Western blot analysis demonstrating the expression of P-gp in total protein extracts from wild-type Chinese hamster ovary cells (AuxB1), drug resistant selected cells (CHORC5), P-gp-knockout drug sensitive cells (AuxB1ΔP−gp), and P-gp-knockout CHORC5 (CHORC5ΔP−gp−A1, and CHORC5ΔP−gp−A3) cells, probed with P-gp-directed monoclonal antibody (C219 mAb) and anti-α-tubulin. α-tubulin expression is shown as a loading control. Panel (B) shows the proliferation of the above cell lines (AuxB1, CHORC5, AuxB1ΔP−gp, CHORC5ΔP−gp−A1, and CHORC5ΔP−gp−A3) without or with increasing molar concentrations of colchicine (0–10 µM) or tamoxifen (0–50 µM). Graphs represent the mean ± SD of three independent experiments done in triplicateCC BY · PubMed Central
Fig. 2 P-gp expression levels and ATPase activity modulate collateral sensitivity to tamoxifen—Panel (A) shows P-gp expression in total cell lysates from drug sensitive (AuxB1 and MDA-MB-231), and – resistant (CHORC5, MDA-Doxo400) cells probed with P-gp-specific monoclonal antibody (C219 mAb) and anti-α-tubulin. Panel (B) shows the proliferation of the above drug sensitive and resistant cell lines (AuxB1, MDA-MB-231, CHORC5, MDA-Doxo400) in the presence of increasing concentrations of tamoxifen, without and with 2 μM PSC-833. Graphs represent the mean ± SD of three independent experiments done in triplicate
Fig. 2 P-gp expression levels and ATPase activity modulate collateral sensitivity to tamoxifen—Panel (A) shows P-gp expression in total cell lysates from drug sensitive (AuxB1 and MDA-MB-231), and – resistant (CHORC5, MDA-Doxo400) cells probed with P-gp-specific monoclonal antibody (C219 mAb) and anti-α-tubulin. Panel (B) shows the proliferation of the above drug sensitive and resistant cell lines (AuxB1, MDA-MB-231, CHORC5, MDA-Doxo400) in the presence of increasing concentrations of tamoxifen, without and with 2 μM PSC-833. Graphs represent the mean ± SD of three independent experiments done in triplicateCC BY · PubMed Central
Fig. 3 Tamoxifen promotes apoptosis in drug resistant cells—Cells were treated for 24 h with tamoxifen prior to quantification of apoptotic cells by flow cytometry or staining with Hoechst 33,258. Panel (A) shows the percentage of AuxB1 and CHORC5 cells stained with FITC-conjugated annexin-V following 24 h treatment with tamoxifen (2.5–10 μM) relative to solvent control. (****), (***) indicates, P < 0.0005, statistically significant difference. Panel (B) shows Hoechst 33,258 stained AuxB1 and CHORC5 cells following 24 h treatment with 5 μM tamoxifen versus solvent control treated cells
Fig. 3 Tamoxifen promotes apoptosis in drug resistant cells—Cells were treated for 24 h with tamoxifen prior to quantification of apoptotic cells by flow cytometry or staining with Hoechst 33,258. Panel (A) shows the percentage of AuxB1 and CHORC5 cells stained with FITC-conjugated annexin-V following 24 h treatment with tamoxifen (2.5–10 μM) relative to solvent control. (****), (***) indicates, P < 0.0005, statistically significant difference. Panel (B) shows Hoechst 33,258 stained AuxB1 and CHORC5 cells following 24 h treatment with 5 μM tamoxifen versus solvent control treated cellsCC BY · PubMed Central
Fig. 4 Overexpression of huBCL-2 diminishes collateral sensitivity to tamoxifen—Panel (A) shows a Western blot of cell extracts from AuxB1, CHORC5, and CHORC5 cells transfected with recombinant human Bcl-2 (CHORC5Bcl−2) probed with anti-Bcl-2 antibody or human-specific anti-Bcl-2 rabbit mAb together with anti-β-actin mAb as loading control. Panel (B) shows the proliferation of AuxB1, CHORC5 and CHORC5BCL2 cell in the presence of increasing concentrations of tamoxifen without and with 2 μM PSC-833. Graphs represent the mean ± SD of three independent experiments done in triplicates
Fig. 4 Overexpression of huBCL-2 diminishes collateral sensitivity to tamoxifen—Panel (A) shows a Western blot of cell extracts from AuxB1, CHORC5, and CHORC5 cells transfected with recombinant human Bcl-2 (CHORC5Bcl−2) probed with anti-Bcl-2 antibody or human-specific anti-Bcl-2 rabbit mAb together with anti-β-actin mAb as loading control. Panel (B) shows the proliferation of AuxB1, CHORC5 and CHORC5BCL2 cell in the presence of increasing concentrations of tamoxifen without and with 2 μM PSC-833. Graphs represent the mean ± SD of three independent experiments done in triplicatesCC BY · PubMed Central
Fig. 5 Tamoxifen treatment modulates the oxidative status of drug resistant cells – The effects of increasing concentrations of tamoxifen on the oxidative status of AuxB1 and CHORC5 cells. Panel (A) and (B) shows drug sensitive (AuxB1) and -resistant (CHORC5) cells incubated without and with tamoxifen (1 and 5 µM) for 24 h followed by a measure of total reduced cellular thiols levels and reactive oxygen species (ROS) in cells. Graphs represent the mean ± SD of three independent experiments done in triplicates. (****) indicates, P < 0.0005, statistically significant difference
Fig. 5 Tamoxifen treatment modulates the oxidative status of drug resistant cells – The effects of increasing concentrations of tamoxifen on the oxidative status of AuxB1 and CHORC5 cells. Panel (A) and (B) shows drug sensitive (AuxB1) and -resistant (CHORC5) cells incubated without and with tamoxifen (1 and 5 µM) for 24 h followed by a measure of total reduced cellular thiols levels and reactive oxygen species (ROS) in cells. Graphs represent the mean ± SD of three independent experiments done in triplicates. (****) indicates, P < 0.0005, statistically significant differenceCC BY · PubMed Central
Fig. 6 Pro- and anti-oxidants modulate collateral sensitivity to tamoxifen – The effects of rotenone (ROT; 1 nM), N-acetyl cysteine (NAC; 0.5 mM) and PSC-833 (2 µM) alone or combined with tamoxifen (1 µM) on the proliferation of AuxB1 and CHORC5. The bar graphs represent the mean ± SD of three independent experiments done in triplicates. (****), (***) indicates, P < 0.0001, statistically significant difference
Fig. 6 Pro- and anti-oxidants modulate collateral sensitivity to tamoxifen – The effects of rotenone (ROT; 1 nM), N-acetyl cysteine (NAC; 0.5 mM) and PSC-833 (2 µM) alone or combined with tamoxifen (1 µM) on the proliferation of AuxB1 and CHORC5. The bar graphs represent the mean ± SD of three independent experiments done in triplicates. (****), (***) indicates, P < 0.0001, statistically significant differenceCC BY · PubMed Central
Fig. 7 Rotenone and tamoxifen synergize to induce collateral sensitivity – Isobole analysis of interactions between tamoxifen and rotenone to induce collateral sensitivity in drug resistant cells (CHORC5). Rotenone shows strong synergistic effect with 0.75 µM tamoxifen at 0.4 nM (Δ) and 1.3 nM (X) for CHORC5. By contrast, at 0.4 nM (Δ) and 1.3 nM (X) rotenone concentrations, with 4 µM tamoxifen, AuxB1 shows moderate to antagonistic drug interactions
Fig. 7 Rotenone and tamoxifen synergize to induce collateral sensitivity – Isobole analysis of interactions between tamoxifen and rotenone to induce collateral sensitivity in drug resistant cells (CHORC5). Rotenone shows strong synergistic effect with 0.75 µM tamoxifen at 0.4 nM (Δ) and 1.3 nM (X) for CHORC5. By contrast, at 0.4 nM (Δ) and 1.3 nM (X) rotenone concentrations, with 4 µM tamoxifen, AuxB1 shows moderate to antagonistic drug interactionsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 63 references

Cited by

See all 10

Metadata

Authors
Bakadlag, R., Limniatis, G., Georges, G., & Georges, E.
Affiliations
  • Collège MacDonald (CA)
  • Institut universitaire de cardiologie et de pneumologie de Québec (CA)
Corresponding author
Georges, Elias
Venue
BMC Cancer
Published
2023-01-06
Volume
23
Issue
1
Pages
24-24
ISSN
1471-2407 (ISSN-L)
OpenAlex
W4313613090
Cited by
9
References
64
Citations by year
2026: 3 · 2025: 1 · 2024: 5
FWCI
1.09
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Cancer (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Natural Sciences and Engineering Research Council of Canada (2017-05009)
Topics
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords
tamoxifen, P-glycoprotein, multidrug resistance, collateral sensitivity, 4-hydroxytamoxifen, reactive oxygen species, oxidative stress, apoptosis, Bcl-2, PSC833, N-acetylcysteine, rotenone, mitochondrial complex I
MeSH terms
Adenosine Triphosphatases, Humans, Receptors, Estrogen, Tamoxifen, Reactive Oxygen Species, Drug Resistance, Multiple, ATP Binding Cassette Transporter, Subfamily B, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-bcl-2, ATP Binding Cassette Transporter, Subfamily B, Member 1, Cell Line, Tumor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The anti-estrogen receptor drug, tamoxifen, is selectively Lethal to P-glycoprotein-expressing Multidrug resistant tumor cells. https://app.cochat.ai/papers/10.1186/s12885-022-10474-x
The paper
Bakadlag, R., Limniatis, G., Georges, G., & Georges, E. (2023). The anti-estrogen receptor drug, tamoxifen, is selectively Lethal to P-glycoprotein-expressing Multidrug resistant tumor cells. BMC Cancer. https://doi.org/10.1186/s12885-022-10474-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.